NAMUR, Belgium, Jan. 3,
2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT:
VNRX) today announced that the Company achieved CE marking on its
Nu.QTM Colorectal Cancer Screening Triage Test on
December 28, 2016, paving the way for
its expected launch across the EU. The novel blood test, developed
at Volition's laboratories in Belgium in conjunction with Hvidovre Hospital
(University of Copenhagen), has
demonstrated the potential to reduce colonoscopies by up to 25%
while maintaining almost 97% detection of colorectal cancer when
combined with the fecal immunochemical test (FIT) score. The
Nu.QTM Triage Test is the first in a pipeline of cancer
screening tests that Volition hopes to bring to market.
Speaking about the CE marking, Cameron
Reynolds, CEO of Volition said: "This is a very exciting
time for Volition as we are coming to market with a product that we
believe meets a pressing and immediate need in many European
countries. This is easily our biggest achievement yet, and is the
result of many years of work from our dedicated team. This
milestone signals our transition from a research and development
phase to a commercial one."
Louise Day, Volition's Chief
Marketing and Communications Officer said, "Being able to offer
European healthcare systems a simple and easy to use blood test
which can be used to triage FIT positive populations for colorectal
cancer has the potential to make a significant difference in many
people's lives and to help health care systems better serve
patients. We have identified the first wave of European countries
for launch and are pleased with the progress we are making."
The most frequently used first line test for colorectal cancer
screening across Europe is the FIT
test. Patients with a positive score following FIT are then
referred for colonoscopy. However, approximately 94.8% of people
who test FIT positive do not have colorectal cancer. This means
that there are a significant number of unnecessary expensive and
invasive colonoscopies performed, placing a severe burden on both
the patient and the healthcare system. Now that it has achieved CE
marking, European patients with a positive FIT score could
subsequently be given the blood-based Nu.QTM Colorectal
Cancer Screening Triage Test and then only be referred for
colonoscopy if the combined test results indicate that it is
necessary; thus potentially reducing colonoscopy referrals by up to
25%.
There are organized colorectal cancer screening programs in 14
of the 28 EU states with a further 10 states offering some form of
public or privately accessible screening. Volition has identified
the initial target governments for its launch in Europe and then intends to roll out the
Nu.QTM test across further territories as part of a five
year plan.
Check out the NEW Corporate Video and Website at
www.volitionrx.com
About Volition
Volition is a life sciences company focused on developing
diagnostic tests for cancer. The tests are based on the science of
Nucleosomics®, which is the practice of identifying and
measuring nucleosomes in the bloodstream or other bodily fluid – an
indication that disease is present.
Volition's goal is to make the tests as easy and simple to use,
for both patients and doctors, as existing diabetic and cholesterol
blood tests. Volition's research and development activities are
currently centered in Belgium as
the company focuses on bringing its diagnostic products to market
first in Europe, then in the U.S.
and ultimately, worldwide.
For more information about Volition, visit Volition's website
(http://www.volitionrx.com) or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter,
LinkedIn, Facebook, and YouTube are not incorporated by reference
into this document and should not be considered part of this
document. The addresses for Volition's website, Twitter,
LinkedIn, Facebook, and YouTube are included in this document as
inactive textual references only.
Media / Investor Contacts
Louise Day,
Volition
L.day@volitionrx.com
+44 (0)7557
774620
|
Scott Powell,
Volition
S.powell@volitionrx.com
+1 (646) 650
1351
|
Tirth Patel,
Edison Advisors
tpatel@edisongroup.com
+1 (646) 653
7035
|
Rachel Carroll,
Edison Advisors
rcarroll@edisongroup.com
+44 (0)20 3077
5711
|
Sarah Roberts,
Vane Percy & Roberts
sarah@vanepercy.com
+44 (0)1737 821
890
|
|
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will," "hopes" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to the effectiveness of the Company's bodily-fluid-based diagnostic
tests as well as the Company's ability to develop and successfully
commercialize such test platforms for early detection of cancer.
The Company's actual results may differ materially from those
indicated in these forward-looking statements due to numerous risks
and uncertainties. For instance, if we fail to develop and
commercialize diagnostic products, we may be unable to execute our
plan of operations. Other risks and uncertainties include the
Company's failure to obtain necessary regulatory clearances or
approvals to distribute and market future products in the clinical
IVD market; a failure by the marketplace to accept the products in
the Company's development pipeline or any other diagnostic products
the Company might develop; the Company will face fierce competition
and the Company's intended products may become obsolete due to the
highly competitive nature of the diagnostics market and its rapid
technological change; and other risks identified in the Company's
most recent Annual Report on Form 10-K and Quarterly Reports on
Form 10-Q, as well as other documents that the Company files with
the Securities and Exchange Commission. These statements are based
on current expectations, estimates and projections about the
Company's business based, in part, on assumptions made by
management. These statements are not guarantees of future
performance and involve risks, uncertainties and assumptions that
are difficult to predict. Forward-looking statements are made as of
the date of this release, and, except as required by law, the
Company does not undertake an obligation to update its
forward-looking statements to reflect future events or
circumstances.
Nucleosomics®, NuQ®, Nu.QTM and HyperGenomics® and
and their respective logos are trademarks and/or service marks of
VolitionRx Limited and its subsidiaries. All other trademarks,
service marks and trade names referred to in this press release are
the property of their respective owners.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/volitionrx-limiteds-novel-cancer-diagnostic-test-achieves-ce-marking-as-it-prepares-for-launch-across-europe-300384375.html
SOURCE VolitionRx Ltd.